Eliquis vs Xarelto
Side-by-side comparison of Eliquis and Xarelto — mechanism, indications, safety, trials, sponsor, and pricing.
At a glance
| Eliquis | Xarelto |
|---|
| Generic name | apixaban | Xarelto |
|---|
| Sponsor | Bristol-Myers Squibb | University Hospital, Montpellier |
|---|
| Drug class | Factor Xa inhibitor | — |
|---|
| Molecular target | Factor Xa (FXa) | Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X |
|---|
| Modality | — | Small molecule |
|---|
| Phase | FDA-approved | FDA-approved |
|---|
| Therapeutic area | Cardiovascular | Oncology |
|---|
| First approval | 2012 | — |
|---|
Mechanism of action
| Eliquis | Apixaban selectively inhibits Factor Xa, decreasing thrombin generation and thrombus development. |
|---|
| Xarelto | — |
|---|
Approved indications
Eliquis
- Arterial embolus and thrombosis
- Myocardial Reinfarction Prevention
Xarelto
- Deep venous thrombosis
- Nonvalvular atrial fibrillation
- Peripheral arterial disease
- Prevention of atherothrombotic events after an acute coronary syndrome
- Prevention of atherothrombotic events at high risk of ischaemic events
- Prevention of atherothrombotic events in symptomatic peripheral artery disease
- Prevention of deep vein thrombosis
- Prevention of pulmonary embolism
Common side effects
Eliquis
- Major Bleeding
- Gastrointestinal Bleeding
- Intracranial Hemorrhage
- Hemorrhagic Stroke
- Other Intracranial Hemorrhage
Further reading